Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ENDP William Blair Comments On Endo Following Proposal To Acquire Auxilium http://www.smarteranalyst.com/2014/09/17/william-blair-comments-on-endo-following-proposal-to-acquire-auxilium/
$CTIC CTI BioPharma: Partnership For Pixuvri Highlights Potential, Says H.C. Wainwright http://www.smarteranalyst.com/2014/09/17/cti-biopharma-partnership-for-pixuvri-highlights-potential-says-h-c-wainwright/
$CTIC CTI BioPharma: Partnership For Pixuvri Highlights Potential, Says H.C. Wainwright http://www.smarteranalyst.com/2014/09/17/cti-biopharma-partnership-for-pixuvri-highlights-potential-says-h-c-wainwright/
$PDLI Janney Capital Remains Neutral On PDL Biopharma Following The Resign Of Ernst & Young http://www.smarteranalyst.com/2014/09/17/janney-capital-remains-neutral-on-pdl-biopharma-following-the-resign-of-ernst-young/
$CTIC Janney Reiterates Buy On Cell Therapeutics Following Collaboration Agreement With Servier http://www.smarteranalyst.com/2014/09/17/janney-reiterates-buy-on-cell-therapeutics-following-collaboration-agreement-with-servier/
$CTIC Janney Reiterates Buy On Cell Therapeutics Following Collaboration Agreement With Servier http://www.smarteranalyst.com/2014/09/17/janney-reiterates-buy-on-cell-therapeutics-following-collaboration-agreement-with-servier/
Janney Reiterates Buy On Cell Therapeutics Following Collaboration Agreement With Servier http://www.smarteranalyst.com/2014/09/17/janney-reiterates-buy-on-cell-therapeutics-following-collaboration-agreement-with-servier/
$DRTX $MDCO Durata Therapeutics: We Recommend Adding To Positions At These Levels, Says Roth Capital http://www.smarteranalyst.com/2014/09/17/durata-therapeutics-we-recommend-adding-to-positions-at-these-levels-says-roth-capital/
$IMUC Roth Capital Reiterates Buy On ImmunoCellular Following Development Update http://www.smarteranalyst.com/2014/09/17/roth-capital-reiterates-buy-on-immunocellular-following-development-update/
$NKTR Nektar Therapeutics: Movantik’s Approval Represents The Best Possible Outcome, Says Roth Capital http://www.smarteranalyst.com/2014/09/17/nektar-therapeutics-movantiks-approval-represents-the-best-possible-outcome-says-roth-capital/
$TGTX Roth Capital Remains Positive On TG Therapeutics Following Discussions With Management http://www.smarteranalyst.com/2014/09/17/roth-capital-remains-positive-on-tg-therapeutics-following-discussions-with-management/
$TGTX Roth Capital Remains Positive On TG Therapeutics Following Discussions With Management http://www.smarteranalyst.com/2014/09/17/roth-capital-remains-positive-on-tg-therapeutics-following-discussions-with-management/
$AXAS Canaccord Reiterates Buy On Abraxas On The Back Of Q3 Guidance http://www.smarteranalyst.com/2014/09/16/canaccord-reiterates-buy-on-abraxas-on-the-back-of-q3-guidance/
$KMX Wedbush Reiterates Neutral Stance On CarMax Shares, $49 PT http://www.smarteranalyst.com/2014/09/16/wedbush-reiterates-neutral-stance-on-carmax-shares-49-pt/
$BCR William Blair Maintains Market Perform On C.R. Bard Amid Fears Of Quicker Competition In DCBs Than Expected http://www.smarteranalyst.com/2014/09/16/william-blair-maintains-market-perform-on-c-r-bard-amid-fears-of-quicker-competition-in-dcbs-than-expected/
$PCYC William Blair Raises Pharmacyclics PT To $186 Following Imbruvica Contract http://www.smarteranalyst.com/2014/09/16/william-blair-raises-pharmacyclics-pt-to-186-following-imbruvica-contract/
$PCYC William Blair Raises Pharmacyclics PT To $186 Following Imbruvica Contract http://www.smarteranalyst.com/2014/09/16/william-blair-raises-pharmacyclics-pt-to-186-following-imbruvica-contract/
We Continue To Believe That Shares Of Agile Hold A Strong Risk/Reward Profile, Says William Blair http://www.smarteranalyst.com/2014/09/16/we-continue-to-believe-that-shares-of-agile-hold-a-strong-riskreward-profile-says-william-blair/
Roth Capital Raises Superior Drilling Price Target To $8 http://www.smarteranalyst.com/2014/09/16/roth-capital-raises-superior-drilling-price-target-to-8/
$NKTR Nektar: Movantik Approval Unlocks Significant Economic Value for Nektar, Says William Blair http://www.smarteranalyst.com/2014/09/16/nektar-movantik-approval-unlocks-significant-economic-value-for-nektar-says-william-blair/
$NKTR Nektar: Movantik Approval Unlocks Significant Economic Value for Nektar, Says William Blair http://www.smarteranalyst.com/2014/09/16/nektar-movantik-approval-unlocks-significant-economic-value-for-nektar-says-william-blair/
$NKTR UPDATE: Brean Capital Raises Nektar Price Target To $20 On The Heels Of FDA Approval Of Movantik http://www.smarteranalyst.com/2014/09/16/update-brean-capital-raises-nektar-price-target-to-20-on-the-heels-of-fda-approval-of-movantik/
$CNCE $AVNR Roth Capital Highlights Key Points From Concert’s Partner Avanir Positive Phase II Results Of AVP-923 http://www.smarteranalyst.com/2014/09/16/roth-capital-highlights-key-points-from-concerts-partner-avanir-positive-phase-ii-results-of-avp-923/
Roth Capital Highlights Key Points From Concert’s Partner Avanir Positive Phase II Results Of AVP-923 http://www.smarteranalyst.com/2014/09/16/roth-capital-highlights-key-points-from-concerts-partner-avanir-positive-phase-ii-results-of-avp-923/
$ONCS OncoSec Represents An Undervalued Player With Significant Upside For The Long-Term Investor, Says HC Wainwright http://www.smarteranalyst.com/2014/09/16/oncosec-represents-an-undervalued-player-with-significant-upside-for-the-long-term-investor-says-h-c-wainwright/
OncoSec Represents An Undervalued Player With Significant Upside For The Long-Term Investor, Says HC Wainwright http://www.smarteranalyst.com/2014/09/16/oncosec-represents-an-undervalued-player-with-significant-upside-for-the-long-term-investor-says-h-c-wainwright/
$CPRX Catalyst: Roth Capital Expects Positive Results From Phase 3 Study Of Firdapse http://www.smarteranalyst.com/2014/09/16/catalyst-roth-capital-expects-positive-results-from-phase-3-study-of-firdapse/
$CPRX Catalyst: Roth Capital Expects Positive Results From Phase 3 Study Of Firdapse http://www.smarteranalyst.com/2014/09/16/catalyst-roth-capital-expects-positive-results-from-phase-3-study-of-firdapse/
$LF LeapFrog: Roth Capital Provides Highlights From Recent Investor Meetings http://www.smarteranalyst.com/2014/09/16/leapfrog-roth-capital-provides-highlights-from-recent-investor-meetings/
$LF LeapFrog: Roth Capital Provides Highlights From Recent Investor Meetings
$KERX H.C. Wainwright Remains Bullish On Keryx Following Ferric Citrate FDA Approval http://www.smarteranalyst.com/2014/09/16/h-c-wainwright-remains-bullish-on-keryx-following-ferric-citrate-fda-approval/
$RATE Bankrate: We Can No Longer Have A Constructive View Of The Stock, Says Topeka http://www.smarteranalyst.com/2014/09/16/bankrate-we-can-no-longer-have-a-constructive-view-of-the-stock-says-topeka/
$RARE Cowen Sees Ultragenyx Shares Outperforming Following Phase 1/2 Data http://www.smarteranalyst.com/2014/09/16/cowen-sees-ultragenyx-shares-outperforming-following-phase-12-data/
$RARE Cowen Sees Ultragenyx Shares Outperforming Following Phase 1/2 Data http://www.smarteranalyst.com/2014/09/16/cowen-sees-ultragenyx-shares-outperforming-following-phase-12-data/
$RARE Cowen Sees Ultragenyx Shares Outperforming Following Phase 1/2 Data http://www.smarteranalyst.com/2014/09/16/cowen-sees-ultragenyx-shares-outperforming-following-phase-12-data/
$BIIB Cowen Comments On Biogen’s Price Increase; Keeps $389 Price Target
http://www.smarteranalyst.com/2014/09/16/cowen-comments-on-biogens-price-increase-keeps-389-price-target/
$BIIB Cowen Comments On Biogen’s Price Increase; Keeps $389 Price Target
http://www.smarteranalyst.com/2014/09/16/cowen-comments-on-biogens-price-increase-keeps-389-price-target/
$V Argus Reiterates Hold On Visa Amid Risks Over Short Term Revenue
http://www.smarteranalyst.com/2014/09/16/argus-reiterates-hold-on-visa-amid-risks-over-short-term-revenue/
$PIR Argus Maintains Buy On Pier 1 Ahead Of 2Q14 Earnings Report http://www.smarteranalyst.com/2014/09/16/argus-maintains-buy-on-pier-1-ahead-of-2q14-earnings-report/
$PIR Argus Maintains Buy On Pier 1 Ahead Of 2Q14 Earnings Report http://www.smarteranalyst.com/2014/09/16/argus-maintains-buy-on-pier-1-ahead-of-2q14-earnings-report/